Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Award of the Dr A.T. Shousha Foundation Prize and Fellowship To Dr. Walid Ammar



Regional Committee for the Eastern Mediterranean                                                                    EM/RC63/INF.DOC.7 Rev.1
Sixty-third session                                                                                                                                           September 2016 
Provisional agenda item 9(a)


Award of the Dr A.T. Shousha Foundation Prize and Fellowship
 
  1. Following the recommendations of the Dr A.T. Shousha Foundation Committee at the Sixty-second Session of the World Health Organization (WHO) Regional Committee for the Eastern Mediterranean, the Executive Board awarded the Dr A.T. Shousha Foundation Prize for 2016, by decision EB138(5), to Dr Walid Ammar (Lebanon) for his significant contribution to public health in the geographical area in which Dr Shousha served WHO.
 
  1. Dr Walid Ammar is being honoured for his significant contribution to public health in Lebanon, in particular in the areas of primary health care and health policy, and for his efforts in translating research and evidence into policy, programmes and practice and his efforts to voice the interests of the Region in all WHO forums. Dr Ammar graduated from the medical college of the Université Libre de Bruxelles, Belgium, in 1982, and received a master’s degree in public health and a diplôme d’études approfondies from the Lebanese University in 1996. In 2001, he was awarded a PhD in epidemiology from the Université Victor Segalen in Bordeaux, France (Université Bordeaux II).
 
  1. Since 1993, Dr Ammar has been Director-General of the Ministry of Public Health of Lebanon, bringing together a range of stakeholders to chart a vision for the welfare, rights and health care in an open network model of governance. Among other achievements, Dr Ammar set up Lebanon’s primary health care network in 1994 and initiated the first national hospital accreditation system in the Eastern Mediterranean Region, and was instrumental in strengthening and developing the Lebanese health care system. In a time of political instability and under his leadership, reforms led to significant improvement in health indicators while decreasing the GDP share of health expenditures, mostly as a result of meaningful reduction in household out-of-pocket spending.
 
  1. Dr Ammar is a model for public health professionals, having served not only in government and in the academic community but also in numerous national, regional and international organizations, boards and councils. Dr Ammar has produced numerous publications in the areas of health systems, health reform and good governance. His work as a researcher has led to the development of major studies which have been pivotal in reforming the health care system of Lebanon. 
Attribution du Prix et de la Bourse d’études de la Fondation Dr A.T. Shousha a Dr. Walid Ammar
 
Awarding Ceremony, Cairo, October 3, 2016-Laureat address-Walid Ammar MD, Ph.D



    ...
    18
    ...
ATC Name B/G Ingredients Dosage Form Price
A10BD20 EMPAZIMET G Metformin HCl - 1000mg, Empagliflozin - 12.5mg Tablet, film coated 1,840,168 L.L
A10BD20 FLORIMET 5/1000 G Metformin - 1000mg, Empagliflozin - 12.5mg Tablet, film coated 1,836,585 L.L
A10BD20 SYNJARDY B Empagliflozin - 12.5mg, Metformin HCl - 850mg 12.5mg/850mg Tablet, film coated 3,287,711 L.L
A10BD20 SYNJARDY B Empagliflozin - 5mg, Metformin HCl - 850mg 5mg/850mg Tablet, film coated 3,287,711 L.L
A10BD20 SYNJARDY B Empagliflozin - 5mg, Metformin HCl - 1000mg 5mg/1000mg Tablet, film coated 3,399,653 L.L
A10BD20 EMPAZIMET G Metformin HCl - 1000mg, Empagliflozin - 5mg Tablet, film coated 1,840,168 L.L
A10BD20 FLORIMET 5/1000 G Metformin - 1000mg, Empagliflozin - 5mg Tablet, film coated 1,836,585 L.L
A10BD21 ENFORZA B Saxagliptin HCl - 5mg, Dapagliflozin - 10mg Tablet, film coated 6,072,824 L.L
A10BF01 GLUFIX G Acarbose - 50mg 50mg Tablet 1,294,120 L.L
A10BG03 ACTOS B Pioglitazone HCl - 30mg 30mg Tablet 2,484,765 L.L
A10BG03 PIODIAB 30 G Pioglitazone HCl - 30mg 30mg Tablet 2,111,753 L.L
A10BG03 ACTOS B Pioglitazone HCl - 15mg 15mg Tablet 1,243,054 L.L
A10BG03 PIODIAB 15 G Pioglitazone HCl - 15mg 15mg Tablet 1,053,317 L.L
A10BG03 UNIGLIT G Pioglitazone HCl - 15mg 15mg Tablet 685,360 L.L
A10BH01 JANUVIA B Sitagliptin - 100mg 100mg Tablet, film coated 1,884,067 L.L
A10BH01 SAGIFOR G Sitagliptin (HCl monohydrate) - 100mg 100mg Tablet, film coated 1,242,606 L.L
A10BH01 SITAGLIPTINE ARROW G Sitagliptin - 100mg 100mg Tablet, coated 1,154,361 L.L
A10BH01 SITAGLIPTINE ARROW G Sitagliptin - 50mg 50mg Tablet, coated 1,139,578 L.L
A10BH02 GALVUS B Vildagliptin - 50mg 50mg Tablet 950,097 L.L
A10BH02 GLUNORM G Vildagliptin - 50mg 50mg Tablet 611,448 L.L
A10BH02 VILDAVITAE G Vildagliptin - 50mg 50mg Tablet 665,202 L.L
A10BH02 VILDIAB G Vildagliptin - 50mg 50mg Tablet 806,306 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
A10BH04 VIPIDIA B Alogliptin benzoate - 25mg 25mg Tablet, film coated 2,998,113 L.L
A10BH05 TRAJENTA B Linagliptin - 5mg 5mg Tablet, film coated 3,213,127 L.L
A10BH05 INAGLIP G Linagliptin - 5mg 5mg Tablet, film coated 1,242,606 L.L
A10BJ02 SAXENDA BioTech Liraglutide - 6mg/ml 6mg/ml Injectable solution 16,747,035 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 0.75mg/0.5ml 0.75mg/0.5ml Injectable solution 10,165,201 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 1.5mg/0.5ml 1.5mg/0.5ml Injectable solution 10,165,201 L.L
    ...
    18
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025